267 related articles for article (PubMed ID: 27893423)
21. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
[TBL] [Abstract][Full Text] [Related]
22. [Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].
Nong J; Qin N; Wang J; Yang X; Zhang H; Wu Y; Lv J; Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2013 May; 16(5):240-5. PubMed ID: 23676980
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Liu GF; Li XF; Yu SN; Miao YY; Zhang SH
J Cell Physiol; 2019 Apr; 234(4):3445-3457. PubMed ID: 30374969
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
Liu D; Zhang L; Wu Y; Jiang J; Tan F; Wang Y; Liu Y; Hu P
Lung Cancer; 2015 Sep; 89(3):262-7. PubMed ID: 26162563
[TBL] [Abstract][Full Text] [Related]
25. Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Jiang Z; Zhang J; Sun H; Wang C; Zhang Y; Li Y; Pan Z
Thorac Cancer; 2021 Sep; 12(17):2369-2374. PubMed ID: 34255422
[TBL] [Abstract][Full Text] [Related]
26. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of the Efficacy and Safety of Icotinib with Standard Second-line
Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
Yao S; Qian K; Wang R; Li Y; Zhang Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):369-73. PubMed ID: 26104894
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
Fan Y; Huang Z; Fang L; Miao L; Gong L; Yu H; Yang H; Lei T; Mao W
Cancer Chemother Pharmacol; 2015 Sep; 76(3):517-23. PubMed ID: 26148750
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.
Xu J; Liu X; Yang S; Zhang X; Shi Y
Asia Pac J Clin Oncol; 2017 Dec; 13(6):379-384. PubMed ID: 28276163
[TBL] [Abstract][Full Text] [Related]
30. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Shi YK; Wang L; Han BH; Li W; Yu P; Liu YP; Ding CM; Song X; Ma ZY; Ren XL; Feng JF; Zhang HL; Chen GY; Han XH; Wu N; Yao C; Song Y; Zhang SC; Song W; Liu XQ; Zhao SJ; Lin YC; Ye XQ; Li K; Shu YQ; Ding LM; Tan FL; Sun Y
Ann Oncol; 2017 Oct; 28(10):2443-2450. PubMed ID: 28945850
[TBL] [Abstract][Full Text] [Related]
31. [The therapeutic value and safety of icotinib as first-line therapy for advanced non-small cell lung cancer patients].
Chen H; Wang HP; Zhang L; Si XY
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):39-43. PubMed ID: 28056322
[No Abstract] [Full Text] [Related]
32. Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.
Ma XH; Tian TD; Liu HM; Li QJ; Gao QL; Li L; Shi B
Eur Rev Med Pharmacol Sci; 2017 Jan; 21(2):266-274. PubMed ID: 28165562
[TBL] [Abstract][Full Text] [Related]
33. Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer.
Shi B; Zhang XB; Xu J; Huang XE
Asian Pac J Cancer Prev; 2015; 16(13):5521-4. PubMed ID: 26225704
[TBL] [Abstract][Full Text] [Related]
34. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Fan Y; Xu Y; Gong L; Fang L; Lu H; Qin J; Han N; Xie F; Qiu G; Huang Z
Sci Rep; 2017 Mar; 7():45193. PubMed ID: 28332624
[TBL] [Abstract][Full Text] [Related]
35. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
He J; Su C; Liang W; Xu S; Wu L; Fu X; Zhang X; Ge D; Chen Q; Mao W; Xu L; Chen C; Hu B; Shao G; Hu J; Zhao J; Liu X; Liu Z; Wang Z; Xiao Z; Gong T; Lin W; Li X; Ye F; Liu Y; Ma H; Huang Y; Zhou J; Wang Z; Fu J; Ding L; Mao L; Zhou C
Lancet Respir Med; 2021 Sep; 9(9):1021-1029. PubMed ID: 34280355
[TBL] [Abstract][Full Text] [Related]
36. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
[TBL] [Abstract][Full Text] [Related]
37. [Clinical Analysis of Icotinib on Beneficiary of
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].
Jiang X; Wang W; Zhang Y
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):200-6. PubMed ID: 27118647
[TBL] [Abstract][Full Text] [Related]
38. The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
Hu X; Zhang L; Shi Y; Zhou C; Liu X; Wang D; Song Y; Li Q; Feng J; Qin S; Xv N; Zhou J; Zhang L; Hu C; Zhang S; Luo R; Wang J; Tan F; Wang Y; Ding L; Sun Y
PLoS One; 2015; 10(11):e0142500. PubMed ID: 26599904
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
40. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Gong L; Xiong M; Huang Z; Miao L; Fan Y
Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
